106 related articles for article (PubMed ID: 19787636)
1. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis.
Rapiti E; Fioretta G; Schaffar R; Neyroud-Caspar I; Verkooijen HM; Schmidlin F; Miralbell R; Zanetti R; Bouchardy C
Cancer; 2009 Dec; 115(23):5556-65. PubMed ID: 19787636
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term mortality with localized prostate cancer.
Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer.
Du XL; Fang S; Vernon SW; El-Serag H; Shih YT; Davila J; Rasmus ML
Cancer; 2007 Aug; 110(3):660-9. PubMed ID: 17582625
[TBL] [Abstract][Full Text] [Related]
4. The impact of socioeconomic status on survival after cancer in the United States : findings from the National Program of Cancer Registries Patterns of Care Study.
Byers TE; Wolf HJ; Bauer KR; Bolick-Aldrich S; Chen VW; Finch JL; Fulton JP; Schymura MJ; Shen T; Van Heest S; Yin X;
Cancer; 2008 Aug; 113(3):582-91. PubMed ID: 18613122
[TBL] [Abstract][Full Text] [Related]
5. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
6. Social class is an important and independent prognostic factor of breast cancer mortality.
Bouchardy C; Verkooijen HM; Fioretta G
Int J Cancer; 2006 Sep; 119(5):1145-51. PubMed ID: 16557599
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
8. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Clin Oncol; 2003 Jun; 21(11):2163-72. PubMed ID: 12775742
[TBL] [Abstract][Full Text] [Related]
9. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
[TBL] [Abstract][Full Text] [Related]
10. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
11. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
Adolfsson J; Tribukait B; Levitt S
Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
[TBL] [Abstract][Full Text] [Related]
12. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
[TBL] [Abstract][Full Text] [Related]
13. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer progression and survival in BRCA2 mutation carriers.
Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
[TBL] [Abstract][Full Text] [Related]
16. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
18. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
Shulman MJ; Benaim EA
Cancer; 2005 Jun; 103(11):2280-6. PubMed ID: 15844202
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
